Frazier leads Series A round for Recida Therapeutics


Recida Therapeutics Inc, a biopharmaceutical company focused on developing treatments for serious antibiotic-resistant infections, has raised $8.5 million in Series A funding. Frazier Healthcare Partners led the round.

Source: Press Release